Results 341 to 350 of about 35,065 (357)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam

Value in Health, 2020
Ong The Due, Ammarin Thakkinstian, Montarat Thavorncharoensap   +2 more
exaly  

Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease

Therapeutic Advances in Gastroenterology, 2016
Robert G Gish
exaly  

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

Leukemia and Lymphoma, 2020
Michele Merli, Carlo Visco, Caroline M Besson   +2 more
exaly  

Current therapy for chronic hepatitis C: The role of direct-acting antivirals

Antiviral Research, 2017
Guangdi Li, Erik De Clercq
exaly  

Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review

Expert Review of Gastroenterology and Hepatology, 2018
Jaume Puig-Junoy, Natàlia Pascual-Argente   +1 more
exaly  

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas

Oncologist, 2019
Michele Merli, Marco Frigeni, Laurent Alric   +2 more
exaly  

Direct-acting antiviral therapy in sub-Saharan Africa

The Lancet Gastroenterology & Hepatology, 2019
C Wendy, Spearman, Mark W, Sonderup
openaire   +2 more sources

Hepatitis C and direct-acting antivirals

Hot Topics in Viral Hepatitis, 2013
openaire   +1 more source

Warfarin: interaction with direct-acting antivirals

Reactions Weekly, 2016
openaire   +1 more source

Outcomes, costs and cost–effectiveness of treating hepatitis C with direct acting antivirals

Journal of Comparative Effectiveness Research, 2015
Jona T Stahmeyer, Christian Krauth
exaly